Powering the microbiome with synthetic biotics
Profile Provided By: Company Website
At Synlogic we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields synthetic biology and the microbiome.Using our synthetic biotics platform we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. We can deliver these synthetic biotics orally where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. We also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical as in stimulation of immune effectors to combat certain tumors.We can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. Our lead programs target patients with rare genetic metabolic diseases including urea cycle disorders (UCD) and phenylketonuria (PKU). We are also hard at work on synthetic biotics to address more prevalent conditions including inflammatory bowel disease (IBD) cancer and metabolic conditions such as diabetes and obesity.
|Human health & social work||C Corporation||Operating||11 - 50 employees|
Funding and Financing Rounds
$40M / Series B
$5M / Series A / Equity
$29,4M / Series A
- Social Policies and Performance
Impact Reports & Metrics
200 Sidney St.
Cambridge, Massachusetts 02139
United States of America